CD4+ lymphocytes modulate prostate cancer progression in mice.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Chronic inflammation is linked to human prostate cancer development.
• Prostate carcinoma emerges in aging Apc(Min/+) mice, mirroring human disease progression.

Purpose of the Study:

• To investigate the role of chronic inflammation and regulatory T cells in prostate cancer development in Apc(Min/+) mice.
• To determine if regulatory T cells can mitigate prostate cancer risk.

Main Methods:

• Utilized Apc(Min/+) mice as a model for prostate cancer.
• Assessed levels of proinflammatory cytokines (IL-6, IL-9) and inflammatory cell infiltrates.
• Manipulated CD4(+)CD25(+) regulatory T (TREG) cells through supplementation and depletion.

Main Results:

• Proinflammatory cytokines correlated with cancer and age in mice, despite minimal inflammatory cell infiltration.
• Lymphocytes, particularly TREG cells, demonstrated a protective effect against prostate cancer.
• TREG cell supplementation reduced IL-6 and IL-9 levels and lowered prostate cancer risk.
• Depletion of CD25(+) cells increased IL-6 expression, prostatic intraepithelial neoplasia, and microinvasive carcinoma.

Conclusions:

• Chronically elevated proinflammatory cytokines drive carcinoma development in Apc(Min/+) mice.
• TREG lymphocytes suppress inflammation-associated carcinogenesis, maintaining immune and epithelial homeostasis.
• TREG cells represent a potential therapeutic strategy for managing prostate cancer.